KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Short-Term Debt issuances (2023)

Supernus Pharmaceuticals (SUPN) has disclosed Short-Term Debt issuances for 1 consecutive years, with $93.0 million as the latest value for Q1 2023.

  • Quarterly Short-Term Debt issuances changed N/A to $93.0 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $93.0 million through Dec 2023, changed N/A year-over-year, with the annual reading at $93.0 million for FY2023, N/A changed from the prior year.
  • Short-Term Debt issuances for Q1 2023 was $93.0 million at Supernus Pharmaceuticals.
  • The five-year high for Short-Term Debt issuances was $93.0 million in Q1 2023, with the low at $93.0 million in Q1 2023.